|1.||Griebel, Guy: 2 articles (01/2009 - 11/2005)|
|2.||Boulay, Denis: 2 articles (01/2009 - 11/2005)|
|3.||Singer, Philipp: 1 article (08/2009)|
|4.||Yee, Benjamin K: 1 article (08/2009)|
|5.||Feldon, Joram: 1 article (08/2009)|
|6.||Black, Mark D: 1 article (01/2009)|
|7.||Barak, Segev: 1 article (01/2009)|
|8.||Varty, Geoffrey B: 1 article (01/2009)|
|9.||Pichat, Philippe: 1 article (01/2009)|
|10.||Weiner, Ina: 1 article (01/2009)|
|1.||Schizophrenia (Dementia Praecox)
08/01/2009 - "According to the glutamatergic hypofunction hypothesis of schizophrenia, SSR504734 may therefore possess antipsychotic potential. "
11/01/2005 - "In conclusion, SSR504734 is a potent and selective GlyT1 inhibitor, exhibiting activity in schizophrenia, anxiety and depression models. "
01/01/2009 - "SSR103800 and SSR504734 are novel glycine transport 1 (GlyT1) inhibitors with therapeutic potential for the treatment of schizophrenia. "
01/01/2006 - "Since glutamate has been shown to play a role in the regulation of the dopaminergic system in dopamine-related disorders, such as schizophrenia, we investigated the possibility that SSR504734 may modify the basolateral amygdala-elicited stimulation of dopamine release in the nucleus accumbens via an augmentation of glutamate receptor-mediated neurotransmission. "
|1.||Glutamic Acid (Glutamate)
|2.||Glutamate Receptors (Glutamate Receptor)
|3.||Glycine (Aminoacetic Acid)